Cell-based therapeutic strategies for multiple sclerosis

Cell-based therapies, including autologous haematopoietic stem cell transplantation, have generated substantial interest as strategies for immune modulation, neuroprotection, or repair of the damaged CNS in multiple sclerosis. Scolding et al. summarise the status of cell-based therapies and make consensus recommendations for future studies and clinical trials.

• Publication year

  2017

• Venue

  Brain : a journal of neurology

• Publication date

  2017-07-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/brain/awx154PMID 29053779PMCID 5841198
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reduced expression of mitochondrial fumarate hydratase in progressive multiple sclerosis contributes to impaired in vitro mesenchymal stromal cell-mediated neuroprotection

  2021cited by this paper
• Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis

  2018cited by this paper
• NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs

  2017cited by this paper
• Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial.

  2017cited by this paper
• Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD.

  2017cited by this paper
• Autologous hematopoietic stem cell transplantation in multiple sclerosis

  2017cited by this paper
• Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis

  2017influential reference
• Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis

  2017cited by this paper
• Pushing Forward: Remyelination as the New Frontier in CNS Diseases.

  2016cited by this paper
• FDA should stand firm on stem-cell treatments

  2016cited by this paper
• Long‐term evolution of multiple sclerosis disability in the treatment era

  2016cited by this paper
• Stem Cells for Multiple Sclerosis

  2016cited by this paper
• Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.

  2016cited by this paper
• Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines

  2016cited by this paper
• Efficacy and safety of ocrelizumab in relapsing multiple sclerosis: Results of the IFN-β-1a-controlled, double-blind, Phase III OPERA I and II studies

  2016influential reference
• Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.

  2016influential reference
• Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid-Dependent Mechanism

  2016cited by this paper
• Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis

  2016cited by this paper
• Survival and Functionality of Human Induced Pluripotent Stem Cell‐Derived Oligodendrocytes in a Nonhuman Primate Model for Multiple Sclerosis

  2016cited by this paper
• Cryopreserved Mesenchymal Stromal Cells Are Susceptible to T‐Cell Mediated Apoptosis Which Is Partly Rescued by IFNγ Licensing

  2016cited by this paper
• Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation

  2016cited by this paper
• Glioproliferative Lesion of the Spinal Cord as a Complication of "Stem-Cell Tourism".

  2016cited by this paper
• Haematopoietic stem cell transplants should be a second-line therapy for highly active MS – NO

  2016cited by this paper
• Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised controlled trial

  2015cited by this paper
• Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis

  2015cited by this paper
• Autologous hematopoietic SCT normalizes miR-16, -155 and -142-3p expression in multiple sclerosis patients

  2015cited by this paper
• Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.

  2015cited by this paper
• Autologous hematopoietic stem cell transplantation in multiple sclerosis

  2015cited by this paper
• Repeat infusion of autologous bone marrow cells in multiple sclerosis: protocol for a phase I extension study (SIAMMS-II)

  2015cited by this paper
• The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review

  2015cited by this paper
• Comparative analysis of human mesenchymal stem cells from bone marrow and adipose tissue under xeno-free conditions for cell therapy

  2015cited by this paper
• Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.

  2015influential reference
• High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.

  2015cited by this paper
• Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

  2015cited by this paper
• Bone Marrow Mesenchymal Stromal Cells Isolated from Multiple Sclerosis Patients have Distinct Gene Expression Profile and Decreased Suppressive Function Compared with Healthy Counterparts

  2015cited by this paper
• Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo

  2015cited by this paper
• Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician’s and patient’s perspectives

  2015influential reference
• Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis

  2015cited by this paper
• Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors

  2015cited by this paper
• The cost of multiple sclerosis drugs in the US and the pharmaceutical industry

  2015cited by this paper
• Patient-Funded Trials: Opportunity or Liability?

  2015cited by this paper
• The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?

  2015cited by this paper
• Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study.

  2015cited by this paper
• Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation

  2014cited by this paper
• Recent Advances in Transplantation for Primary Immune Deficiency Diseases: A Comprehensive Review

  2014cited by this paper
• Therapeutic potential of genetically modified mesenchymal stem cells after neonatal hypoxic-ischemic brain damage.

  2014influential reference
• Multiple sclerosis in children and adolescents: incidence and clinical picture – new insights from the nationwide German surveillance (2009–2011)

  2014cited by this paper
• The epidemiology of multiple sclerosis: insights to disease pathogenesis.

  2014cited by this paper
• Intranasal delivery of central nervous system‐retargeted human mesenchymal stromal cells prolongs treatment efficacy of experimental autoimmune encephalomyelitis

  2014cited by this paper
• The past, present and future of stem cell clinical trials for ALS.

  2014cited by this paper
• Cell fusion in the brain: two cells forward, one cell back

  2014cited by this paper
• Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.

  2014cited by this paper
• Mesenchymal stem/stromal cells as a pharmacological and therapeutic approach to accelerate angiogenesis.

  2014cited by this paper
• Generation of Functional Mesenchymal Stem Cells from Different Induced Pluripotent Stem Cell Lines

  2014cited by this paper
• Effects of hematopoietic stem cell transplantation on acyl-CoA oxidase deficiency: a sibling comparison study

  2014cited by this paper
• Actin Cytoskeletal Disruption following Cryopreservation Alters the Biodistribution of Human Mesenchymal Stromal Cells In Vivo

  2014cited by this paper
• Concise Review: Optimizing Expansion of Bone Marrow Mesenchymal Stem/Stromal Cells for Clinical Applications

  2014cited by this paper
• Donor cell-derived leukemia after cord blood transplantation and a review of the literature: differences between cord blood and BM as the transplant source

  2014cited by this paper
• World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

  2014cited by this paper
• Molecular Characterization of Neurally Differentiated Human Bone Marrow-derived Clonal Mesenchymal Stem Cells

  2014cited by this paper
• Mesenchymal Stem Cells Do Not Prevent Antibody Responses against Human α-L-Iduronidase when Used to Treat Mucopolysaccharidosis Type I

  2014cited by this paper
• Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.

  2014cited by this paper
• Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience

  2014influential reference
• Randomized Placebo-Controlled Phase II Trial of Autologous Mesenchymal Stem Cells in Multiple Sclerosis

  2014cited by this paper
• T cell repertoire following autologous stem cell transplantation for multiple sclerosis.

  2014cited by this paper
• Autologous and allogeneic mesenchymal stem cells in organ transplantation: what do we know about their safety and efficacy?

  2014cited by this paper
• Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis

  2014cited by this paper
• In vitro and in vivo neurogenic potential of mesenchymal stem cells isolated from different sources

  2014cited by this paper
• Characterization of Human Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium Cell Sheets Aiming for Clinical Application

  2014cited by this paper
• The Potential of Human Umbilical Cord-Derived Mesenchymal Stem Cells as a Novel Cellular Therapy for Multiple Sclerosis

  2014cited by this paper
• Transcription factor–mediated reprogramming of fibroblasts to expandable, myelinogenic oligodendrocyte progenitor cells

  2013cited by this paper
• World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

  2013cited by this paper
• Concise Review: Adult Mesenchymal Stem Cells, Adult Neural Crest Stem Cells, and Therapy of Neurological Pathologies: A State of Play

  2013cited by this paper
• Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation

  2013cited by this paper
• Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases.

  2013cited by this paper
• Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis.

  2013cited by this paper
• Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine

  2013cited by this paper
• The cost burden of multiple sclerosis in the United States: a systematic review of the literature

  2013cited by this paper
• Hypoxia Promotes Dopaminergic Differentiation of Mesenchymal Stem Cells and Shows Benefits for Transplantation in a Rat Model of Parkinson’s Disease

  2013cited by this paper
• Mesenchymal stem cells (MSC) derived from mice with experimental autoimmune encephalomyelitis (EAE) suppress EAE and have similar biological properties with MSC from healthy donors.

  2013cited by this paper
• Possible induction of acute disseminated encephalomyelitis (ADEM)-like demyelinating illness by intrathecal mesenchymal stem cell injection.

  2013cited by this paper
• Interactions of environment and genes in multiple sclerosis.

  2013cited by this paper
• Steps Toward Safe Cell Therapy Using Induced Pluripotent Stem Cells

  2013cited by this paper
• Adult Bone Marrow Neural Crest Stem Cells and Mesenchymal Stem Cells Are Not Able to Replace Lost Neurons in Acute MPTP-Lesioned Mice

  2013cited by this paper
• Multipotent mesenchymal stromal cells decrease transforming growth factor β1 expression in microglia/macrophages and down-regulate plasminogen activator inhibitor 1 expression in astrocytes after stroke.

  2013cited by this paper
• iPSC-derived neural precursors exert a neuroprotective role in immune-mediated demyelination via the secretion of LIF

  2013cited by this paper
• In Vivo MR Imaging of Intraarterially Delivered Magnetically Labeled Mesenchymal Stem Cells in a Canine Stroke Model

  2013cited by this paper
• Hematopoietic stem-cell transplantation for sickle cell disease: current evidence and opinions

  2013cited by this paper
• A regenerative approach to the treatment of multiple sclerosis

  2013cited by this paper
• Non-Hodgkin Lymphoma

  2013cited by this paper
• Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis

  2013cited by this paper
• Magnetic resonance contrast and biological effects of intracellular superparamagnetic iron oxides on human mesenchymal stem cells with long-term culture and hypoxic exposure.

  2013cited by this paper
• Engraftment of Human Mesenchymal Stem Cells in a Rat Photothrombotic Cerebral Infarction Model : Comparison of Intra-Arterial and Intravenous Infusion Using MRI and Histological Analysis

  2013cited by this paper
• Blocking LINGO-1 as a Therapy to Promote CNS Repair: From Concept to the Clinic

  2013cited by this paper
• Contribution of cortical lesion subtypes at 7T MRI to physical and cognitive performance in MS

  2013cited by this paper
• Multicontrast MR Imaging at 7T in Multiple Sclerosis: Highest Lesion Detection in Cortical Gray Matter with 3D-FLAIR

  2013cited by this paper
• Recent insights into the pathology of multiple sclerosis and neuromyelitis optica.

  2013cited by this paper
• Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies.

  2012cited by this paper
• Assaying macrophage activity in a murine model of inflammatory bowel disease using fluorine-19 MRI

  2012cited by this paper
• Characterization of Autologous Mesenchymal Stem Cell‐Derived Neural Progenitors as a Feasible Source of Stem Cells for Central Nervous System Applications in Multiple Sclerosis

  2012influential reference

• An Integrated Network Biology and Molecular Dynamics Approach Identifies CD44 as a Promising Therapeutic Target in Multiple Sclerosis.

  2026cites this paper
• Treatment strategies for multiple sclerosis in middle-aged and older adults

  2025cites this paper
• Applicability of regenerative oligodendrocyte precursor cell optic nerve transplantation in rat model of demyelinating disease

  2025cites this paper
• Decoding the molecular and cellular aspects of multiple sclerosis: From diagnosis to therapeutic strategies.

  2025cites this paper
• Role of peroxisome proliferator-activated receptor alpha in neurodegenerative diseases and other neurological disorders: Clinical application prospects

  2025cites this paper
• Neuroprotective strategies in multiple sclerosis: a status update and emerging paradigms

  2025cites this paper
• Interaction Between Neutrophils and Elements of the Blood–Brain Barrier in the Context of Multiple Sclerosis and Ischemic Stroke

  2025influential citation
• Kinetics of serum NFL and GFAP and changes in cognitive functions, in MS patients treated with repeated administrations of autologous mesenchymal stem cells (MSC-NG01).

  2025cites this paper
• Biomarker Identification in Patients with Multiple Sclerosis Treated with Autologous Hematopoietic Stem Cell Transplantation

  2025cites this paper
• A Review of the Pathogenesis and Treatment Options of Multiple Sclerosis

  2025cites this paper
• Patient-reported outcomes of quality of life before and after autologous hematopoietic stem cell transplantation for multiple sclerosis

  2025cites this paper
• Targeting SMOX Preserves Optic Nerve Myelin, Axonal Integrity, and Visual Function in Multiple Sclerosis

  2025cites this paper
• Oligodendrocyte Injury in Multiple Sclerosis.

  2025cites this paper
• Intranasal delivery systems for traumatic brain injury: Advancements and perspectives

  2025cites this paper
• The role of type I collagen in white matter injury.

  2025cites this paper
• Immunological Tolerance Induced by Nanoliposome with Autoantigenie Peptide and Artesunate to Inhibit Complement and Remodel Immune Balance for Multiple Sclerosis Treatment

  2025cites this paper
• Processing and sectioning of organ donor spinal cord tissue for electrophysiology on acute human spinal cord slices

  2025cites this paper
• Cell Therapy in Multiple Sclerosis: Clinical Advances, Limitations, and Future Perspectives from Clinical Studies—A Systematic Review

  2025cites this paper
• Optimizing Human Nasal Turbinate Stem Cell Dosage for the Effective Treatment of Empty Nose Syndrome

  2025cites this paper
• Human Umbilical Cord–Derived Mesenchymal Stem Cells in the Treatment of Multiple Sclerosis Patients: Phase I/II Dose-Finding Clinical Study

  2024cites this paper
• Oligodendrocyte Progenitor Cell Transplantation Reduces White Matter Injury in a Fetal Goat Model

  2024cites this paper
• Human iPSC-derived neural stem cells displaying radial glia signature exhibit long-term safety in mice

  2024cites this paper
• Nano-based approaches for the treatment of neuro-immunological disorders: a special emphasis on multiple sclerosis

  2024cites this paper
• The Therapeutic Potential of Exosomes from Mesenchymal Stem Cells in Multiple Sclerosis

  2024cites this paper
• Glial Cells as Key Regulators in Neuroinflammatory Mechanisms Associated with Multiple Sclerosis

  2024cites this paper
• Overview of emerging therapies for demyelinating diseases

  2024cites this paper
• Economics of hematopoietic stem cell transplant in immune-mediated neurologic autoimmune diseases.

  2024cites this paper
• Oligodendrocyte precursor cell-derived exosomes combined with cell therapy promote clinical recovery by immunomodulation and gliosis attenuation

  2024cites this paper
• Cell‐based therapy for diabetic cardiovascular complications: Prospects and challenges

  2024cites this paper
• Safety and Efficacy of Bone Marrow and Adipose Tissue-Derived Mesenchymal Stem Cells for the Treatment of Ischemic Stroke: A Systematic Review.

  2024cites this paper
• Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019

  2023cites this paper
• Potential of Nano-Engineered Stem Cells in the Treatment of Multiple Sclerosis: A Comprehensive Review

  2023cites this paper
• The Bone Marrow Microenvironment in Immune-Mediated Inflammatory Diseases: Implications for Mesenchymal Stromal Cell-Based Therapies

  2023cites this paper
• Cell replacement therapy with stem cells in multiple sclerosis, a systematic review

  2023cites this paper
• The neuroprotective potential of mesenchymal stem cells from bone marrow and human exfoliated deciduous teeth in a murine model of demyelination

  2023cites this paper
• Electroacupuncture at ST36 acupoint regulates stem cells during experimental autoimmune encephalomyelitis.

  2023cites this paper
• Effect of Hematopoietic Stem Cell Transplantation and Post-Transplantation Cyclophosphamide on the Microglia Phenotype in Rats with Experimental Allergic Encephalomyelitis

  2023cites this paper
• OCT4-induced oligodendrocyte progenitor cells promote remyelination and ameliorate disease

  2022cites this paper
• Advances in nanotechnology versus stem cell therapy for the theranostics of multiple sclerosis disease

  2022cites this paper
• Stem cell therapy for cuprizone model of multiple sclerosis focusing on the effectiveness of different injection methods and cell labeling.

  2022cites this paper
• Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis

  2022cites this paper
• The genealogy, methodology, similarities and differences of immune reconstitution therapies for multiple sclerosis and neuromyelitis optica.

  2022cites this paper
• Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: YES

  2022cites this paper
• Research Progress of Flavonoid Chinese Herbal Extract Monomers in Multiple Sclerosis

  2022cites this paper
• Protocol for the treatment of patients with multiple sclerosis using bone marrow stromal cells (BMSC) in the State Institution "Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine"

  2022cites this paper
• Triboelectric Nanogenerators for Cellular Bioelectrical Stimulation

  2022cites this paper
• The Effect of Methylene Blue and Its Metabolite—Azure I—on Bioenergetic Parameters of Intact Mouse Brain Mitochondria

  2022cites this paper
• Intracellular and Extracellular Antifreeze Protein Significantly Improves Mammalian Cell Cryopreservation

  2022cites this paper
• Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT

  2022cites this paper
• Potential application of hydrogel to the diagnosis and treatment of multiple sclerosis

  2022cites this paper
• Repeat infusion of autologous bone marrow cells in progressive multiple sclerosis - A phase I extension study (SIAMMS II).

  2022cites this paper
• A chemically defined biomimetic surface for enhanced isolation efficiency of high-quality human mesenchymal stromal cells under xenogeneic/serum-free conditions.

  2022cites this paper
• The Integration of Cell Therapy and Biomaterials as Treatment Strategies for Remyelination

  2022cites this paper
• Effects of Mesenchymal Stem Cell Transplantation on Cerebrospinal Fluid Biomarkers in Progressive Multiple Sclerosis

  2022cites this paper
• Pathways to cures for multiple sclerosis: A research roadmap

  2022cites this paper
• Repair Effects of Bone Marrow Mesenchymal Stem Cells on Demyelination of Trigeminal Ganglion in Rats with Trigeminal Neuralgia

  2022cites this paper
• Rg1 exerts protective effect in CPZ-induced demyelination mouse model via inhibiting CXCL10-mediated glial response

  2021cites this paper
• Treating MS After 50: the Role of Age in Therapeutic Decision-Making

  2021cites this paper
• [Effect of methylene blue and its metabolite - azure I - on bioenergetic parameters of intact mice brain mitochondria].

  2021cites this paper
• A chemically defined biomimetic surface for enhanced isolation efficiency of high-quality human mesenchymal stromal cells under xeno-/serum-free conditions

  2021cites this paper
• Mesenchymal stromal cell apoptosis is required for their therapeutic function

  2021cites this paper
• A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis.

  2021cites this paper
• Mesenchymal stem cells for multiple sclerosis: hype or hope?

  2021cites this paper
• Multiple sclerosis and its impact on dental care

  2021cites this paper
• The protective effects of neural stem cells and neural stem cells-conditioned medium against inflammation-induced prenatal brain injury.

  2021cites this paper
• Developing a New Strategy for Delivery of Neural Transplant Populations Using Precursor Cell Sprays and Specialized Cell Media

  2021cites this paper
• Long-Term Clinical and Immunological Effects of Repeated Mesenchymal Stem Cell Injections in Patients With Progressive Forms of Multiple Sclerosis

  2021cites this paper
• Stem Cell Therapies for Progressive Multiple Sclerosis

  2021cites this paper
• Mesenchymal Stem Cells: An Excellent Candidate for the Treatment of Diabetes Mellitus

  2021cites this paper
• A review of possible therapies for multiple sclerosis

  2021cites this paper
• Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review

  2021cites this paper
• Synergistic neuroprotective effects of Fingolimod and Mesenchymal Stem Cells (MSC) in Experimental Autoimmune Encephalomyelitis.

  2021cites this paper
• Brain implants

  2020cites this paper
• Decoding intrathecal immunoglobulins and B cells in the CNS: their synthesis, function, and regulation

  2020cites this paper
• New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis

  2020cites this paper
• Intranasal administration of conditioned medium derived from mesenchymal stem cells-differentiated oligodendrocytes ameliorates experimental autoimmune encephalomyelitis.

  2020cites this paper
• Regulatory B Cells Normalize CNS Myeloid Cell Content in a Mouse Model of Multiple Sclerosis and Promote Oligodendrogenesis and Remyelination

  2020cites this paper
• Promises and Limitations of Neural Stem Cell Therapies for Progressive Multiple Sclerosis.

  2020cites this paper
• Adipose mesenchymal stem cell transplantation alleviates spinal cord injury-induced neuroinflammation partly by suppressing the Jagged1/Notch pathway

  2020cites this paper
• Standard Operating Procedure for the Good Manufacturing Practice-Compliant Production of Human Endometrial Stem Cells for Multiple Sclerosis.

  2020cites this paper
• Transplantation of induced neural stem cells (iNSCs) into chronically demyelinated corpus callosum ameliorates motor deficits

  2020cites this paper
• Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis

  2020cites this paper
• Mesenchymal Stem Cells Attenuated Blood-Brain Barrier Disruption via Downregulation of Aquaporin-4 Expression in EAE Mice

  2020cites this paper
• Particles Containing Cells as a Strategy to Promote Remyelination in Patients With Multiple Sclerosis

  2020cites this paper
• Delay of gCJD aggravation in sick TgMHu2ME199K mice by combining NPC transplantation and Nano-PSO administration.

  2020cites this paper
• IV/IT hUC-MSCs Infusion in RRMS and NMO: A 10-Year Follow-Up Study

  2020cites this paper
• Amnion-Derived Multipotent Progenitor Cells Suppress Experimental Optic Neuritis and Myelitis

  2020cites this paper
• Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis: Recommendations of the National Multiple Sclerosis Society.

  2020cites this paper
• Stem Cell-based Therapy for Neurodegenerative Diseases

  2020cites this paper
• Future Challenges and Perspectives for Stem Cell Therapy of Neurodegenerative Diseases.

  2020cites this paper
• The therapeutic potential of exogenous adult stem cells for the injured central nervous system

  2020cites this paper
• Intranasal Delivery: Effects on the Neuroimmune Axes and Treatment of Neuroinflammation

  2020cites this paper
• Combining miR-23b exposure with mesenchymal stem cell transplantation enhances therapeutic effects on EAE.

  2020cites this paper
• Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis.

  2020cites this paper
• Mesenchymal stem cells instruct a beneficial phenotype in reactive astrocytes

  2020cites this paper
• MicroRNA 182 promotes T helper 1 cell by repressing hypoxia induced factor 1 alpha in experimental autoimmune encephalomyelitis

  2019cites this paper
• Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: A Meta-Analysis

  2019cites this paper
• Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies

  2019cites this paper
• Remyelination Pharmacotherapy Investigations Highlight Diverse Mechanisms Underlying Multiple Sclerosis Progression.

  2019cites this paper
• The Importance of HLA Assessment in “Off-the-Shelf” Allogeneic Mesenchymal Stem Cells Based-Therapies

  2019cites this paper